PDL Biopharma Second Quarter 2011 Net Income was $70.0 Million PDL Biopharma Second Quarter 2011 Net Income was $70.0 Million

PDL Biopharma Second Quarter 2011 Net Income was $70.0 Million

Biotech Financial Reports 2011, August 1, 18, 8

    • $5.99
    • $5.99

Publisher Description

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), Incline Village, Nev. reported financial results for the second quarter ended June 30, 2011. Total revenues for the second quarter of 2011 were $122.1 million, compared to $120.3 million for the same period of 2010, a one percent year-over-year increase. Total revenues for the six months ended June 30, 2011, were $205.5 million, compared to $182.4 million for the same period of 2010. Included in results for the six months ended June 30, 2011, and not included in the same period in 2010, is a $10.0 million settlement payment from UCB Pharma S.A. resolving all legal disputes between the two companies. Excluding this one-time payment, revenue increased seven percent year over year for the six month period ended June 30, 2011.

GENRE
Business & Personal Finance
RELEASED
2011
August 1
LANGUAGE
EN
English
LENGTH
8
Pages
PUBLISHER
Worldwide Videotex
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
61.2
KB

More Books Like This

Rambus Reports Second Quarter Earnings; Revenue of $38.9 Million, Loss Per Share of $0.11 Cents for the Second Quarter Rambus Reports Second Quarter Earnings; Revenue of $38.9 Million, Loss Per Share of $0.11 Cents for the Second Quarter
2010
Neovasc Inc. Reports Financial Results for the Second Quarter of 2010 Neovasc Inc. Reports Financial Results for the Second Quarter of 2010
2010
Vista Gold Corp. Announces Second Quarter Financial Results and Conference Call with Management Vista Gold Corp. Announces Second Quarter Financial Results and Conference Call with Management
2010
Supergen has 2009 3RD Qtr Total Revenues of $10.4 Million (Financial Report) Supergen has 2009 3RD Qtr Total Revenues of $10.4 Million (Financial Report)
2009
Zila Reports Fiscal 2009 3rd QTR Net Revenues of $8.5 Mil (Financial Report) Zila Reports Fiscal 2009 3rd QTR Net Revenues of $8.5 Mil (Financial Report)
2009
PAR Pharmaceutical Annual Revenue Tops $1.0 Billion (Financial Report) PAR Pharmaceutical Annual Revenue Tops $1.0 Billion (Financial Report)
2011

More Books by Biotech Financial Reports

Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer
2008
Avigen Reports Net Loss of $7.3 MIL for 2nd QTR 2008 (Financial Report) Avigen Reports Net Loss of $7.3 MIL for 2nd QTR 2008 (Financial Report)
2008
Sangamo Reports Net Loss of $7.4 MIL for 2nd QTR 2008 (Financial Report) Sangamo Reports Net Loss of $7.4 MIL for 2nd QTR 2008 (Financial Report)
2008
Delglobal has Fiscal 2008 3rd QTR Net Loss of $1.6 Mil (Financial Report) Delglobal has Fiscal 2008 3rd QTR Net Loss of $1.6 Mil (Financial Report)
2008
Gilead Sciences Reports 2nd QTR Revenues of $1.28 Billion (Financial Report) Gilead Sciences Reports 2nd QTR Revenues of $1.28 Billion (Financial Report)
2008
Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report) Curis Reports First QTR 2008 Net Loss of $3.4 Million (Financial Report)
2008